Why is Celcuity (CELC) stock down today?

Celcuity stock fell 17.60% to $91.51 on July 15, 2026 — after opening as high as $98.00 and touching a session low of $85.00 — in a classic 'sell the news' reaction. The company had just received its first-ever U.S. FDA approval for REVTORPYK, a drug treating advanced HR+/HER2- breast cancer (a hormone-receptor-positive, HER2-negative form of the disease). Despite the milestone, investors focused on the news that the commercial launch of REVTORPYK will be delayed, meaning revenue from the drug will arrive later than the market had expected.

The mechanism behind the drop is straightforward: biotech stocks are frequently priced well in advance of anticipated catalysts like FDA approvals. Once the approval was confirmed but accompanied by a pushback in launch timing, traders who had bought in anticipation of the event sold their positions. Reuters specifically cited the delayed breast cancer drug launch as eclipsing the approval itself. Competition in the HR+/HER2- breast cancer market — where Pfizer (PFE) is also a player based on related ticker references — adds further pressure on Celcuity's commercial prospects.

Analyst sentiment remained constructive even as the stock sold off. Citizens analyst Silvan Turkcan maintained a Market Outperform rating and raised his price target from $160 to $177. HC Wainwright & Co. analyst Swayampakula Ramakanth also kept a Buy rating and raised his target from $145 to $155. However, at least one Seeking Alpha analysis noted that the outlook is tempered by phase 3 trial data, competitive dynamics, and the launch timing issue — factors that weighed on the stock despite the bullish analyst calls.

The broader market was not to blame for the decline: the S&P 500 was up 0.38% on the day and QQQ was only marginally lower at -0.27%, making CELC's drop a company-specific event. Celcuity carries a market cap of approximately $4.46 billion. The company reported a last-quarter loss per share of $0.86, slightly better than the estimated loss of $0.89, with no product revenue recorded — reflecting its pre-commercial stage at that time.

As of the close of trading on July 15, Celcuity has completed its first FDA approval and is now a commercial-stage company, though revenue realization depends on the timing of the REVTORPYK launch. The delay in that launch is the central fact driving the stock's current position.